Community News

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. “We are […]

IRVINE, Calif.--(BUSINESS WIRE)--Nihon Kohden, a U.S. market leader in precision medical products and services, today announced that it is rebranding Nihon Kohden USLab, its Irvine-based R&D and product development subsidiary, to Nihon Kohden Digital Health Solutions Inc. The name change reflects the company’s evolution toward creating a digital health ecosystem to complement its capital equipment offerings with the vision of helping customers achieve better patient outcomes and improve […]

LONDON & LOS ANGELES--(BUSINESS WIRE)--Crescent Capital Group LP, a leading alternative asset management firm, announced today that its European Specialty Lending strategy has provided refinancing to the existing banking facilities of Avania, a leading global full-service contract research organization (“CRO”) focused on medical technology development. Avania is a portfolio company of Kester Capital. Terms of the financing were not disclosed. Headquartered in Bilthoven, the Netherlands […]

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2020. Key highlights include: Net sales of $73.2 million in Q4 2020, compared to $65.8 million in Q4 2019. Glaucoma net sales of $58.4 million and Corneal Health net sales of $14

LOS ANGELES & CASTRES, France--(BUSINESS WIRE)--Puma Biotechnology and Pierre Fabre added Greater China to their license agreement. Puma and CANbridge Pharma terminated their Greater China agreement

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology released its financial results for the fourth quarter and year ended Dec. 31, 2020 on Feb. 25, 2020.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that U.S. Phase 3 pivotal trial results for its next-generation corneal cross-linking iLink™ therapy for the treatment of keratoconus, known as Epi-on, met the study’s primary efficacy endpoint, demonstrating a statistically significant improvement […]

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported results for the fourth quarter and fiscal year ended December 31, 2020. Raymond W. Cohen, Axonics CEO, said, “In the first year of Axonics’ commercial launch in the United States, we exceeded our ambitious goals […]

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that it has acquired privately-held Contura Ltd. and its flagship product, Bulkamid, a best-in-class urethral bulking agent for women with stress urinary incontinence (SUI). Axonics acquired London-based Contura Ltd. f

SANTA MONICA, Calif.--(BUSINESS WIRE)-- #Biomed--Organizers of BIOMEDevice and Medical Design & Manufacturing (MD&M), today announced MD&M | BIOMEDigital, a two-day virtual conference.

IRVINE, Calif.--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the Cowen 41st Annual Healthcare Conference, which takes place March 1-4, 2021. Company management will be scheduling meetings with investors on Thursday, March 4. Meetings may be scheduled through Cowen. About Agendia Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and t

MONROVIA, Calif. & LOS ANGELES--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and UCLA Technology Development Group (UCLA TDG) today announced an agreement to develop novel therapeutic antibodies, pairing novel targets proposed by scientists at UCLA and utilizing Xencor's modular suite of XmAb® technology platforms. Xencor and UCLA have […]

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”), Glass, Lewis & Co., LLC (“Glass Lewis”), and Egan-Jones Proxy Services (“Egan-Jones”) have recommended NantKwest stockholders vote “FOR” the pending merger with ImmunityBio. ISS concluded in its February 24, 2021 report: “Both NK and […]

ALISO VIEJO, Calif.--(BUSINESS WIRE)--BrainChip Inc. and NaNose Medical Successfully Detect COVID-19 in Exhaled Breath with Fast High-Accuracy Results

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the fourth quarter and fiscal year ended January 1, 2021. Fourth Quarter 2020 Overview Net Sales of $46.0 Million Up 18% from the Prior Year Quarter ICL Sales of $39.8 Million Up 20% from the Prior Year Quarter ICL Units Up 13% from the Prior Year Quarter Gross Margin at

MORENO VALLEY, Calif.--(BUSINESS WIRE)--BioLife Plasma Services announces expansion of plasma donation centers into California.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Raymond James 42nd Annual Institutional Investors Conference on Wednesday, March 3, 2021 at 3:50 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global medical technology company that develops

LOS ANGELES--(BUSINESS WIRE)-- #AppliedVR--AppliedVR, a pioneer advancing the next generation of digital medicine, today announced results from its pivotal randomized controlled trial (RCT), evaluating virtual reality (VR) therapy for treating chronic pain at home. The study, which was published in Journal of Medical Internet Research (JMIR), found that AppliedVR’s EaseVRx device produced “clinically meaningful” improvement in multiple pain outcomes, and had high participant satisfaction […]

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #COVID19research--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19” were published Feb. 20 on medRxiv, a preprint publication website. The Phase 3 study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving an added nutritional protocol. Aimed at improving […]

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended January 2, 2021. Fourth Quarter 2020 Results: Total revenue for the fourth quarter of 2020, including royalty and other revenue, increased 19.2% to $295.1 million, compared to $247.5 million in the fourth quarter of 2019. Product revenue increased 19.2% to $295.1 million, or 18.1% on a constant currency basis, compared to $247.4 million in the fourth quarter of